Home > Insider Trading > Filing (0000899243-20-018256)

Filing Details

Accession Number:: 0000899243-20-018256
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-02 16:02:27
Reporting Period:: 2020-06-30

Accepted Time:: 2020-07-02 16:02:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1805890	Fusion Pharmaceuticals Inc.	FUSN	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1645161	Healthcap Vii, L.p.	C/O Healthcap Vii Gp S.a., 18 Avenue Of D'Ouchy Lausanne V8 CH-1006		No	No	Yes	No
1790047	S.a. Gp Vii Healthcap	C/O Healthcap Vii Gp S.a., 18 Avenue Of D'Ouchy Lausanne V8 CH-1006		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-06-30	2,497,345	$0.00	2,497,345	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-30	1,069,902	$0.00	3,567,247	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-30	240,000	$17.00	3,807,247	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Class A Preferred Exchangeable Shares	Disposition	2020-06-30	13,333,333	$0.00	2,497,345	$0.00
Common Shares	Class B Preferred Exchangeable Shares	Disposition	2020-06-30	5,712,216	$0.00	1,069,902	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.
The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.